Teva Emalex Acquisition: Ecopipam for Tourette Syndrome
Review Teva's $700M acquisition of Emalex Biosciences. Explore how ecopipam, a dopamine D1 antagonist, advances pediatric Tourette syndrome and CNS therapies.
Back to Articles
Articles tagged with “dopamine-d1-antagonist”